Literature DB >> 24091827

An evaluation of the effects of acute and chronic L-tyrosine administration on BDNF levels and BDNF mRNA expression in the rat brain.

Gabriela K Ferreira1, Giselli Scaini, Isabela C Jeremias, Milena Carvalho-Silva, Cinara L Gonçalves, Talita C B Pereira, Giovanna M T Oliveira, Luiza W Kist, Maurício R Bogo, Patrícia F Schuck, Gustavo C Ferreira, Emilio L Streck.   

Abstract

Tyrosinemia type II, which is also known as Richner-Hanhart syndrome, is an inborn error of metabolism that is due to a block in the transamination reaction that converts tyrosine to p-hydroxyphenylpyruvate. Because the mechanisms of neurological dysfunction in hypertyrosinemic patients are poorly known and the symptoms of these patients are related to the central nervous system, the present study evaluated brain-derived neurotrophic factor (BDNF) levels and bdnf mRNA expression in young rats and during growth. In our acute protocol, Wistar rats (10 and 30 days old) were killed 1 h after a single intraperitoneal L-tyrosine injection (500 mg/kg) or saline. Chronic administration consisted of L-tyrosine (500 mg/kg) or saline injections 12 h apart for 24 days in Wistar rats (7 days old), and the rats were killed 12 h after the last injection. The brains were rapidly removed, and we evaluated the BDNF levels and bdnf mRNA expression. The present results showed that the acute administration of L-tyrosine decreased both BDNF and bdnf mRNA levels in the striatum of 10-day-old rats. In the 30-day-old rats, we observed decreased BDNF levels without modifications in bdnf transcript level in the hippocampus and striatum. Chronic administration of L-tyrosine increased the BDNF levels in the striatum of rats during their growth, whereas bdnf mRNA expression was not altered. We hypothesize that oxidative stress can interact with the BDNF system to modulate synaptic plasticity and cognitive function. The present results enhance our knowledge of the pathophysiology of hypertyrosinemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24091827     DOI: 10.1007/s12035-013-8552-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  48 in total

1.  Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal.

Authors:  Subbiah Pugazhenthi; Ketaki Phansalkar; Gerald Audesirk; Anne West; Leigh Cabell
Journal:  Free Radic Biol Med       Date:  2005-09-02       Impact factor: 7.376

2.  Functional trkB neurotrophin receptors are intrinsic components of the adult brain postsynaptic density.

Authors:  K Wu; J L Xu; P C Suen; E Levine; Y Y Huang; H T Mount; S Y Lin; I B Black
Journal:  Brain Res Mol Brain Res       Date:  1996-12-31

Review 3.  Development of the cerebral cortex in rodents and man.

Authors:  H B Uylings
Journal:  Eur J Morphol       Date:  2000-12

4.  Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor.

Authors:  S J Mowla; H F Farhadi; S Pareek; J K Atwal; S J Morris; N G Seidah; R A Murphy
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

5.  BDNF or IGF-I potentiates free radical-mediated injury in cortical cell cultures.

Authors:  B J Gwag; J Y Koh; M M Chen; L L Dugan; M M Behrens; D Lobner; D W Choi
Journal:  Neuroreport       Date:  1995-12-29       Impact factor: 1.837

6.  Chronic hyperhomocysteinemia alters antioxidant defenses and increases DNA damage in brain and blood of rats: protective effect of folic acid.

Authors:  Cristiane Matté; Vanize Mackedanz; Francieli M Stefanello; Emilene B S Scherer; Ana C Andreazza; Caroline Zanotto; Angela M Moro; Solange C Garcia; Carlos A Gonçalves; Bernardo Erdtmann; Mirian Salvador; Angela T S Wyse
Journal:  Neurochem Int       Date:  2008-10-14       Impact factor: 3.921

7.  Regional tyrosine levels in rat brain after tyrosine administration.

Authors:  M C Morre; F Hefti; R J Wurtman
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

8.  Brain-derived neurotrophic factor (BDNF) overexpression in the forebrain results in learning and memory impairments.

Authors:  Carla Cunha; Andrea Angelucci; Angela D'Antoni; Mate D Dobrossy; Stephen B Dunnett; Nicoletta Berardi; Riccardo Brambilla
Journal:  Neurobiol Dis       Date:  2008-11-27       Impact factor: 5.996

Review 9.  From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning.

Authors:  William J Tyler; Mariana Alonso; Clive R Bramham; Lucas D Pozzo-Miller
Journal:  Learn Mem       Date:  2002 Sep-Oct       Impact factor: 2.460

Review 10.  Painful keratoderma and photophobia: hallmarks of tyrosinemia type II.

Authors:  L G Rabinowitz; L R Williams; C E Anderson; A Mazur; P Kaplan
Journal:  J Pediatr       Date:  1995-02       Impact factor: 4.406

View more
  8 in total

1.  Evidence of hippocampal astrogliosis and antioxidant imbalance after L-tyrosine chronic administration in rats.

Authors:  Milena Carvalho-Silva; Lara M Gomes; Samira Dal-Toé de Prá; Leticia B Wessler; Patricia F Schuck; Giselli Scaini; Andreza Fabro de Bem; Carlos H Blum-Silva; Flávio H Reginatto; Jade de Oliveira; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2019-11-08       Impact factor: 3.584

2.  Omega-3 fatty acid supplementation decreases DNA damage in brain of rats subjected to a chemically induced chronic model of Tyrosinemia type II.

Authors:  Milena Carvalho-Silva; Lara M Gomes; Giselli Scaini; Joyce Rebelo; Adriani P Damiani; Maiara Pereira; Vanessa M Andrade; Fernanda F Gava; Samira S Valvassori; Patricia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2017-03-18       Impact factor: 3.584

3.  Antioxidants reverse the changes in energy metabolism of rat brain after chronic administration of L.-tyrosine.

Authors:  Brena P Teodorak; Giselli Scaini; Milena Carvalho-Silva; Lara M Gomes; Letícia J Teixeira; Joyce Rebelo; Samira D T De Prá; Neila Zeni; Patrícia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2016-12-06       Impact factor: 3.584

4.  The characterization of neuroenergetic effects of chronic L-tyrosine administration in young rats: evidence for striatal susceptibility.

Authors:  Gabriela K Ferreira; Milena Carvalho-Silva; Lara M Gomes; Giselli Scaini; Leticia J Teixeira; Isabella T Mota; Patrícia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2014-09-25       Impact factor: 3.584

5.  Omega-3 fatty acid supplementation can prevent changes in mitochondrial energy metabolism and oxidative stress caused by chronic administration of L-tyrosine in the brain of rats.

Authors:  Milena Carvalho-Silva; Lara M Gomes; Maria L Gomes; Bruna K Ferreira; Patricia F Schuck; Gustavo C Ferreira; Felipe Dal-Pizzol; Jade de Oliveira; Giselli Scaini; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2019-04-04       Impact factor: 3.584

6.  Role of antioxidant treatment on DNA and lipid damage in the brain of rats subjected to a chemically induced chronic model of tyrosinemia type II.

Authors:  Emilio L Streck; Samira D T De Prá; Paula Ronsani Ferro; Milena Carvalho-Silva; Lara M Gomes; Jotele F Agostini; Adriani Damiani; Vanessa M Andrade; Patrícia F Schuck; Gustavo C Ferreira; Giselli Scaini
Journal:  Mol Cell Biochem       Date:  2017-05-25       Impact factor: 3.396

7.  Antioxidants Reverse the Changes in the Cholinergic System Caused by L-Tyrosine Administration in Rats.

Authors:  Lara M Gomes; Giselli Scaini; Milena Carvalho-Silva; Maria L Gomes; Fernanda Malgarin; Luiza W Kist; Maurício R Bogo; Eduardo Pacheco Rico; Alexandra I Zugno; Pedro F P Deroza; Gislaine Z Réus; Airam B de Moura; João Quevedo; Gustavo C Ferreira; Patrícia F Schuck; Emilio L Streck
Journal:  Neurotox Res       Date:  2018-02-07       Impact factor: 3.911

8.  Towards resolving the enigma of the dichotomy of resveratrol: cis- and trans-resveratrol have opposite effects on TyrRS-regulated PARP1 activation.

Authors:  Megha Jhanji; Chintada Nageswara Rao; Mathew Sajish
Journal:  Geroscience       Date:  2020-11-27       Impact factor: 7.713

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.